Naoko Takebe

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. ncbi Methotrexate selection of long-term culture initiating cells following transduction of CD34(+) cells with a retrovirus containing a mutated human dihydrofolate reductase gene
    Naoko Takebe
    Program of Molecular Pharmacology and Experimental Therapeutics, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Gene Ther 9:308-20. 2002
  2. ncbi Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients
    Naoko Takebe
    University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201, USA
    Clin Cancer Res 10:8301-8. 2004
  3. ncbi IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells
    Naoko Takebe
    University of Maryland Greenebaum Cancer Center, 655 West Baltimore Street, BRB 7 029, Baltimore, MD 21201, USA
    Mol Cancer Ther 5:457-66. 2006
  4. ncbi A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer
    Paul K Paik
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lung Cancer 74:481-5. 2011
  5. ncbi Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene
    Gina M Capiaux
    Graduate School of Medical Sciences, Cornell University, New York, NY 10021, USA
    Cancer Gene Ther 11:767-73. 2004
  6. ncbi Retroviral transduction of a mutant dihydrofolate reductase-thymidylate synthase fusion gene into murine marrow cells confers resistance to both methotrexate and 5-fluorouracil
    Gina M Capiaux
    Graduate School of Medical Sciences, Cornell University, New York, NY 10021, USA
    Hum Gene Ther 14:435-46. 2003
  7. ncbi RCAS/SCL-TVA animal model allows targeted delivery of polyoma middle T oncogene to vascular endothelial progenitors in vivo and results in hemangioma development
    Justin Sausville
    Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA
    Clin Cancer Res 14:3948-55. 2008
  8. ncbi Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients
    Ashraf Z Badros
    Greenebaum Cancer Center, Department of Pathology, University of Maryland, 22 S Greene St, Baltimore, MD 21201, USA
    J Clin Oncol 23:4089-99. 2005
  9. ncbi A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies
    Paul K Paik
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Chemother Pharmacol 66:1079-85. 2010
  10. ncbi Human brain endothelial cells (HUBEC) promote SCID repopulating cell expansion through direct contact
    Xiangfei Cheng
    Greenebaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA
    Growth Factors 25:141-50. 2007

Collaborators

Detail Information

Publications14

  1. ncbi Methotrexate selection of long-term culture initiating cells following transduction of CD34(+) cells with a retrovirus containing a mutated human dihydrofolate reductase gene
    Naoko Takebe
    Program of Molecular Pharmacology and Experimental Therapeutics, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Gene Ther 9:308-20. 2002
    ..These are the first investigations to demonstrate selection for transduced long-term culture initiating cells using MTX. The DHFR/MTX system holds promise for improving selection of gene-transduced hematopoietic progenitor cells in vivo...
  2. ncbi Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients
    Naoko Takebe
    University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201, USA
    Clin Cancer Res 10:8301-8. 2004
    ..On the basis of our preclinical studies, we designed a clinical study to test our hypothesis that MMF has antimyeloma activity...
  3. ncbi IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells
    Naoko Takebe
    University of Maryland Greenebaum Cancer Center, 655 West Baltimore Street, BRB 7 029, Baltimore, MD 21201, USA
    Mol Cancer Ther 5:457-66. 2006
    ..In summary, MMF attenuates G1-S phase cell cycle progression and activates the pathway of mitochondrial dysfunction, leading to cytochrome c release followed by activation of caspases...
  4. ncbi A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer
    Paul K Paik
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lung Cancer 74:481-5. 2011
    ..Based on these data, we performed a phase II study of obatoclax mesylate plus topotecan in patients with relapsed SCLC to assess efficacy...
  5. ncbi Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene
    Gina M Capiaux
    Graduate School of Medical Sciences, Cornell University, New York, NY 10021, USA
    Cancer Gene Ther 11:767-73. 2004
    ..Co-expression of mutant DHFR and TS enzymes has additive effects in conferring resistance to pemetrexed-induced toxicity. This construct may be useful for conferring myeloprotection to patients receiving this drug...
  6. ncbi Retroviral transduction of a mutant dihydrofolate reductase-thymidylate synthase fusion gene into murine marrow cells confers resistance to both methotrexate and 5-fluorouracil
    Gina M Capiaux
    Graduate School of Medical Sciences, Cornell University, New York, NY 10021, USA
    Hum Gene Ther 14:435-46. 2003
    ..As MTX and 5-FU are used in combination therapy for diseases such as breast and colon cancer, this fusion gene may be useful in the clinic to reduce myelosuppressive toxicity associated with this drug combination...
  7. ncbi RCAS/SCL-TVA animal model allows targeted delivery of polyoma middle T oncogene to vascular endothelial progenitors in vivo and results in hemangioma development
    Justin Sausville
    Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA
    Clin Cancer Res 14:3948-55. 2008
    ..To recapitulate the generation of cancer stem cells in the context of an intact animal using a retroviral vector capable of in vivo delivery of oncogenes to primitive endothelial and hematopoietic stem cells...
  8. ncbi Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients
    Ashraf Z Badros
    Greenebaum Cancer Center, Department of Pathology, University of Maryland, 22 S Greene St, Baltimore, MD 21201, USA
    J Clin Oncol 23:4089-99. 2005
    ..Bcl-2 regulates the mitochondrial apoptosis pathway that promotes chemotherapy resistance. Bcl-2 antisense oligonucleotide, G3139, targets Bcl-2 mRNA...
  9. ncbi A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies
    Paul K Paik
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Chemother Pharmacol 66:1079-85. 2010
    ....
  10. ncbi Human brain endothelial cells (HUBEC) promote SCID repopulating cell expansion through direct contact
    Xiangfei Cheng
    Greenebaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA
    Growth Factors 25:141-50. 2007
    ..We conclude that the successful expansion by HUBEC contact culture is a candidate explanation based on the Wnt family protein, possibly Wnt3, expression on HUBEC...
  11. ncbi Preliminary findings on the use of pulsatile machine reperfusion of a placenta to improve the cord blood collection yield including primitive hematopoietic stem cell fractions
    Naoko Takebe
    Greenebaum Cancer Center and Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland, USA
    Transfusion 49:1911-6. 2009
    ..This study demonstrates for the first time the feasibility of pulsatile machine placenta reperfusion (PMPR), which significantly improves CB collection quantity and quality compared to standard collection methods...
  12. ncbi Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies
    Ivana Gojo
    University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Leuk Res 31:1165-73. 2007
    ..2-5.5 microM) was above levels required to achieve in vitro/in vivo leukemia growth inhibition. Based on these data, we conclude that Triapine warrants further investigation in hematologic malignancies...
  13. ncbi Multiple myeloma presenting initially as a solitary pleural effusion later complicated by malignant plasmacytic ascites
    Yoshio Inoue
    University of Maryland, School of Medicine, Department of Medicine, 22 South Greene Street Baltimore, MD 21201, USA
    Leuk Res 29:715-8. 2005
    ..Involvement of serous cavities in myeloma carries a poor prognosis, and there is currently no standard effective treatment regimen...
  14. ncbi KIT as a therapeutic target in metastatic melanoma
    Richard D Carvajal
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    JAMA 305:2327-34. 2011
    ..We explored the effects of KIT inhibition using imatinib mesylate in this molecular subset of disease...